Results 201 to 210 of about 3,898,138 (262)

Discovery and Optimization of AMT‐676, a CDH17‐Targeting ADC for the Treatment of Advanced Gastrointestinal Cancers

Advanced Science, EarlyView.
AMT‐676 is a novel antibody‐drug conjugate targeting CDH17, an adhesion molecule uniquely exposed on gastrointestinal tumor surfaces. Engineered with an optimized exatecan payload, it demonstrates profound tumor regression and a robust bystander effect across diverse preclinical models.
Ying‐nan Wang, Dan‐yun Ruan, Jing Shi, Yue Huang, Hui Sheng, Ya‐ling Huang, Linjie Ma, Lijun Wang, Caiwei Chen, Yixuan Wang, Yue Zhang, Yi Shen, Qing Zhang, Jianjian Zhang, Yanfang Tang, Jin‐ling Zhang, Jia‐jia Hu, Chen‐yi Wu, Jia‐ying Chen, Xun Meng, Shu‐Hui Liu, Feng Wang   +21 more
wiley   +1 more source

Epigenetic Reactivation of TNFRSF19 Suppresses Mitophagy and Sensitizes Triple‐Negative Breast Cancer to Doxorubicin

Advanced Science, EarlyView.
TNFRSF19 is an epigenetically silenced regulator of mitophagy in triple‐negative breast cancer. TNFRSF19 deficiency activates the TGFBR1–SMAD3–PINK1 axis to promote mitophagy and confer doxorubicin resistance, whereas decitabine‐mediated restoration of TNFRSF19 suppresses mitophagy and enhances doxorubicin sensitivity, revealing a targetable epigenetic–
Shiyang Liu, Chenguang Liu, Weihong Zheng, Xiaofei Tong, Zhengwei Gui, Zonghong Lu, Sun Ieong, Lin Zhang   +7 more
wiley   +1 more source

Targeting LDHA Palmitoylation Sensitizes GBM to Chemoradiotherapy via Suppressing Palmitic Acid Induced Glycolytic Reprogramming

Advanced Science, EarlyView.
Mesenchymal GSCs preferentially uptake palmitic acid, thereby promoting ZDHHC12‐mediated LDHA palmitoylation. This modification enhances LDHA enzymatic activity, drives glycolytic reprogramming, and facilitates exosomal LDHA‐mediated TAM regulation.
Zijie Gao, Rongrong Zhao, Zheyuan Chen, Qingtong Wang, Huanyu Yang, Boyan Li, Yanhua Qi, Shulin Zhao, Jixing Zhao, Jiawei Qiu, Ziwen Pan, Zhe Han, Ruochuan Li, Huize Xia, Weijie Tang, Xing Guo, Ping Zhang, Hongyu Zhao, Xu Qian, Gang Li, Hao Xue   +20 more
wiley   +1 more source

An Injectable Metal‐Drug Supramolecular Condensate Enables Radiosensitization and Systemic Antitumor Immunity for Post‐Surgical Osteosarcoma Therapy

Advanced Science, EarlyView.
This work designed an injectable metal‐drug supramolecular condensate formed from hafnium ions and alendronate (Hf‐ALN) and loaded with the COX‐2 inhibitor celecoxib (CXB) for synergistic radioimmunotherapy of postoperative osteosarcoma. Mechanistically, upon X‐ray irradiation, Hf enhances radiation energy deposition, ROS generation, and DNA damage ...
Tianhua Xiao, Zunlei Gong, Chuke Chen, Hui Yu, Yu Cai, Can Liu, Hongkai Huang, Ying Li, Jinyuan Guan, Le Wang, Chengyun Ning, Guoxin Tan, Lei Zhou   +12 more
wiley   +1 more source

Ultrasound‐Activated Nanoinhibitors Blocking the Chemo‐Immune Checkpoint to Overcome Chemotherapy‐Induced Immune Resistance

Advanced Science, EarlyView.
A sono‐responsive chemo‐immune checkpoint nanoinhibitor (Sono‐TT8) co‐delivering TPZ chemotherapy and siXkr8 simultaneously kills tumor cells and blocks PS externalization, reversing chemotherapy‐induced immunosuppression and enhancing antitumor immunity. ABSTRACT Breast cancer features an immunosuppressive tumor microenvironment following chemotherapy
Yunfan Liu, Chier Du, Leilei Zhu, Hongjin An, Shengzhe Hou, Yi Lan, Xuemei Tang, Min Xu, Peng Luo, Hua Teng, Hao Yang, Xun Guo, Jianli Ren, Zhiyi Zhou   +13 more
wiley   +1 more source

Multifunctional Nanovaccine‐Radiotherapy Synergy Drives Anti‐Tumor Immunity via Multi‐Cascade Cell Death for Pancreatic Cancer Therapy

Advanced Science, EarlyView.
Machine‐learning‐driven transcriptomic analysis identifies FSTL3 as a key tumor‐microenvironment regulator in desmoplastic pancreatic adenocarcinoma. A cRGD‐modified liposome co‐loading gemcitabine and siFSTL3 serves as an irradiation‐triggered in situ nanovaccine. It synergizes with radiotherapy to induce ferroptosis and immunogenic cell death through
Chengyi Huang, Yushu Han, Xiang Liu, Chuanhao Wang, Xiaofei Zhu, Di Chen, Yangyang Gong, Liang Chen, Wenjuan Chen, Zhenyuan Miao, Bufu Tang, Huojun Zhang   +11 more
wiley   +1 more source

DDX21 Enhances Radiosensitivity in Head and Neck Squamous Cell Carcinoma by Suppressing MK2‐Mediated DNA Damage Response

Advanced Science, EarlyView.
DDX21 suppresses MK2 activation by directly inhibiting Thr334 phosphorylation in a p38‐independent manner, thereby impairing DNA damage response. Clinically, patients with well‐differentiated tumors exhibiting high DDX21 expression are more likely to benefit from adjuvant radiotherapy, whereas those with low DDX21 levels are predisposed to ...
Tianru Yang, Ting Shen, Yanfang Qiu, Wei Zhang, Ziran Zheng, Jiayi Sun, Yuedi Yao, Mianfeng Yao, Jiang Li   +8 more
wiley   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Radiotherapy of cervical cancer

Cancer/Radiothérapie, 2022
External beam radiotherapy and brachytherapy are major treatments in the management of cervical cancer. For early-stage tumours with local risk factors, brachytherapy is a preoperative option. Postoperative radiotherapy is indicated according to histopathological criteria.
C, Chargari, K, Peignaux, A, Escande, S, Renard, C, Lafond, A, Petit, D, Lam Cham Kee, C, Durdux, C, Haie-Méder   +8 more
openaire   +2 more sources

Radiotherapy for hypopharynx cancers

Cancer/Radiothérapie, 2022
We present the update of the recommendations of the French society of oncological radiotherapy on radiotherapy for hypopharynx. Intensity-modulated radiotherapy is the gold standard treatment for hypopharynx cancers. Early T1 and T2 tumors could be treated by exclusive radiotherapy or surgery followed by postoperative radiotherapy in case of high ...
Pointreau, Y., Biau, J., Delaby, N., Thariat, J., Lapeyre, M.   +4 more
openaire   +3 more sources

Rectal cancer radiotherapy

Cancer/Radiothérapie, 2022
We present the updated recommendations of the French society of oncological radiotherapy for rectal cancer radiotherapy. The standard treatment for locally advanced rectal cancer consists in chemoradiotherapy followed by radical surgery with total mesorectal resection and adjuvant chemotherapy according to nodal status.
Vendrely, V., Rivin del Campo, E., Modesto, A., Jolnerowski, M., Meillan, N., Chiavassa, S., Serre, A.-A., Gérard, J.-P., Créhanges, G., Huguet, F., Lemanski, C., Peiffert, D.   +11 more
openaire   +2 more sources